Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed May 10, 2022 · 10-Q · 40 days after period end · 0001628280-22-013677
| Metric | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|
| Revenue | $55.16M | $48.58M | — |
| Net Income | $19.29M | $5.69M | -$45.09K |
| EPS Diluted | $0.21 | -$0.02 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end
